Pulmatrix, Inc. (NASDAQ:PULM) Short Interest Update

Pulmatrix, Inc. (NASDAQ:PULMGet Free Report) saw a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 8,000 shares, an increase of 27.0% from the January 31st total of 6,300 shares. Currently, 0.2% of the company’s shares are sold short. Based on an average daily volume of 18,400 shares, the short-interest ratio is presently 0.4 days.

Pulmatrix Trading Down 3.8 %

Shares of NASDAQ:PULM opened at $1.92 on Monday. The firm’s 50 day simple moving average is $1.88 and its 200 day simple moving average is $1.99. Pulmatrix has a fifty-two week low of $1.64 and a fifty-two week high of $3.50.

Institutional Trading of Pulmatrix

A number of hedge funds have recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Pulmatrix by 62.9% in the 4th quarter. Vanguard Group Inc. now owns 35,082 shares of the biotechnology company’s stock valued at $65,000 after acquiring an additional 13,548 shares during the period. Susquehanna International Group LLP acquired a new stake in shares of Pulmatrix in the 1st quarter valued at approximately $73,000. Mariner LLC acquired a new stake in shares of Pulmatrix in the 4th quarter valued at approximately $97,000. Citadel Advisors LLC acquired a new stake in Pulmatrix during the 2nd quarter worth approximately $141,000. Finally, Renaissance Technologies LLC raised its holdings in Pulmatrix by 7.3% during the 2nd quarter. Renaissance Technologies LLC now owns 121,920 shares of the biotechnology company’s stock worth $560,000 after buying an additional 8,300 shares during the period. 11.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on shares of Pulmatrix in a research report on Wednesday, February 28th. They set a “hold” rating on the stock.

Read Our Latest Stock Analysis on PULM

Pulmatrix Company Profile

(Get Free Report)

Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.

Featured Stories

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.